TPD & Induced Proximity Summit Leaderboard
  • Saturday, June 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 21

Author

Pharma Journalist 8887 posts 0 comments

FDA Reviews ILUMYA for Psoriatic Arthritis Treatment

Mar 18, 2026
Sun Pharmaceutical Industries Limited has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for…
Read More...

FDA Rejects Reproxalap NDA Over Efficacy Concerns

Mar 18, 2026
Aldeyra Therapeutics has received a setback in its efforts to bring a new treatment for dry eye disease to market, following a Complete Response Letter (CRL) issued by the U.S. Food and…
Read More...

How SmartLab Exchange USA Helped Uncountable Accelerate High‑Value R&D Partnerships

Mar 18, 2026
For fast‑growing digitalization leaders like Uncountable, accessing the right scientific and R&D decision makers is essential. Before joining the SmartLab Exchange USA, the company…
Read More...

Digital Transformation and AI-Powered Discovery in Modern Laboratories

Mar 18, 2026
Across materials science, chemistry, and pharmaceutical R&D, laboratories are moving beyond slow, sequential experimentation toward AI‑integrated discovery. One of the most…
Read More...

Roche Expands AI Infrastructure With Massive GPU Investment

Mar 17, 2026
Roche has announced a major expansion of its global artificial intelligence (AI) infrastructure, unveiling a large-scale “AI factory” powered by next-generation accelerated computing…
Read More...

Sentynl Licenses Progerinin to Expand Progeria Treatment Pipeline

Mar 17, 2026
Sentynl Therapeutics, a U.S.-based biopharmaceutical company and a wholly owned subsidiary of Zydus Lifesciences, has entered into a licensing agreement with South Korea-based PRG…
Read More...

FDA Approves Cosentyx for Pediatric Hidradenitis Suppurativa

Mar 16, 2026
Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of pediatric patients aged 12 years and older with moderate…
Read More...

FDA Expands GSK RSV Vaccine to Younger At-Risk Adults

Mar 16, 2026
GSK plc has announced that the U.S. Food and Drug Administration (FDA) has expanded the approved use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to include adults aged 18…
Read More...

Akeso Advances First Trispecific Antibody Into Clinical Trials

Mar 16, 2026
Akeso, Inc. has announced that its novel trispecific antibody candidate, AK150, has received Investigational New Drug (IND) clearance from the National Medical Products Administration…
Read More...

Earendil Labs Partners WuXi Biologics on Antibody Pipeline

Mar 16, 2026
Earendil Labs has entered into a strategic collaboration with WuXi Biologics to accelerate the development and manufacturing of a portfolio of next-generation biologics, including…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.